Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 27, 2018New England Journal of MedicineOpen Access

Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy

View Full Paper
Ask AI
Bookmark
Share

Authors

MMMatthew J. MaurerGeneral CardiologyJSJeffrey H. SchwartzNational Museum of American HistoryBGBalarama GundapaneniPfizer (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Maurer et al. (2018) studied this question.

synapsesocial.com/papers/69aea7357defb997d5abddb4https://doi.org/10.1056/nejmoa1805689
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Combining mortality and longitudinal measures in clinical trials1999 · 368 citations
  2. 2TTR (Transthyretin) Stabilizers Are Associated With Improved Survival in Patients With TTR Cardiac Amyloidosis2018 · 105 citations
  3. 3Tafamidis in Transthyretin Amyloid Cardiomyopathy2015 · 140 citations
  4. 4A new staging system for cardiac transthyretin amyloidosis2017 · 778 citations
  5. 5Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction2015 · 1,181 citations